Skip to content
Convexity

Companies LLY

2 notes

Eli Lilly, in two notes.

Every dispatch about Eli Lilly (LLY), newest first.

SEC fundamentalsAll companies

The notes

Nov 2, 2026 to Nov 13, 2026

  1. Market notes20 min read

    Novo is selling more Wegovy for less

    Novo Nordisk's U.S. Wegovy sales rose 21% in the third quarter, all of it from a pill that brings in about $179 a prescription. U.S. sales grew 1% as Ozempic lost volume, and Lilly's U.S. tirzepatide sales grew 44%.

  2. Market notes18 min read

    Lilly's prices are falling faster than its headline says

    Eli Lilly's U.S. prices fell 10% in the third quarter before one-time rebate true-ups, not the 7% it reported. Volume, up 53% worldwide, still wins by far. Next year's mix, heavier in Medicare at $245 a month, pushes the price of a prescription lower again.

In the terminal

Eli Lilly in the terminal: the statements, earnings history and charts the notes were written from.

Opens in the Convexity terminal. Signed out, you sign in first and come straight back to the page; an account is free.

Written about alongside

Notes shared with Eli Lilly

  1. NVONovo Nordisk1 note

Open LLY beside NVO in Chart Studio

See Eli Lilly's numbers in the terminal.

Statements, earnings history and charts, on a free account. Founder pricing locked for life.